论文部分内容阅读
目的:检测正常人群血浆凝血酶激活的纤溶抑制物(TAFI):Ag水平并建立正常人参考值范围,探讨其在肾病综合征患者血浆中的变化。方法:酶联免疫吸附试验(ELISA)测定56例肾病综合征患者和90例健康体检者血浆TAFI:Ag的水平。结果:与正常人群血浆TAFI:Ag水平(89.91±25.93)%相比,肾病综合征患者血浆TAFI:Ag水平(146.11±35.09)%显著升高(P<0.01),正常人群血浆TAFI:Ag参考值范围为39.08%～140.73%。结论:正常人群血浆TAFI:Ag含量有较大的差异,肾病综合征患者血浆TAFI:Ag含量显著增高,表明TAFI在肾病综合征的发病中起着一定的作用。
OBJECTIVE: To detect plasma thrombin-activated fibrinolysis inhibitor (TAFI): Ag levels in normal subjects and to establish a normal human reference range to investigate the changes in plasma of nephrotic syndrome patients. Methods: Plasma TAFI: Ag levels were measured in 56 patients with nephrotic syndrome and 90 healthy controls by enzyme-linked immunosorbent assay (ELISA). Results: Plasma levels of TAFI: Ag (146.11 ± 35.09)% in patients with nephrotic syndrome were significantly higher than those in normal controls (89.91 ± 25.93% The value range is 39.08% ~ 140.73%. Conclusion: The plasma TAFI: Ag content in normal population is quite different. The content of plasma TAFI: Ag in patients with nephrotic syndrome is significantly higher, indicating that TAFI plays a role in the pathogenesis of nephrotic syndrome.